Age Dependency of Cerebral P-gp Function Measured with (R)-[11C]verapamil and PET

Overview

Journal Eur J Clin Pharmacol

Specialty Pharmacology

Date 2009 Aug 6

PMID 19655132

Citations 25

Authors

Martin Bauer

Rudolf Karch

Friederike Neumann

Aiman Abrahim

Claudia C Wagner

Kurt Kletter

Markus Muller

Markus Zeitlinger

Oliver Langer

Affiliations

Soon will be listed here.

Abstract

Purpose: The aim of this study was to assess the influence of age on the functional activity of the multidrug efflux transporter P-glycoprotein (P-gp) at the human blood-brain barrier.

Methods: Seven young (mean age: 27 +/- 4 years) and six elderly (mean age: 69 +/- 9 years) healthy volunteers underwent dynamic (R)-[(11)C]verapamil (VPM) positron emission tomography (PET) scans and arterial blood sampling. Parametric distribution volume (DV) images were generated using Logan linearisation, and age groups were compared with statistical parametric mapping (SPM). Brain regions that SPM analysis had shown to be most affected by age were analysed by a region of interest (ROI)-based approach using a maximum probability brain atlas, before and after partial volume correction (PVC).

Results: SPM analysis revealed significant clusters of DV increases in cerebellum, temporal and frontal lobe of elderly compared to younger subjects. In the ROI-based analysis, elderly subjects showed significant DV increases in amygdala (+30%), insula (+26%) and cerebellum (+25%) before PVC, and in insula (+33%) after PVC.

Conclusions: Increased VPM DV values in the brains of elderly subjects suggest a decrease in cerebral P-gp function with increasing age.

Citing Articles

Age of onset for increased dose-adjusted serum concentrations of antidepressants and association with sex and genotype: An observational study of 34,777 individuals.

Tveit K, Hermann M, Nilsen R, Wallerstedt S, Rongve A, Molden E Eur J Clin Pharmacol. 2024; 80(3):435-444.

PMID: 38197945 PMC: 10873233. DOI: 10.1007/s00228-023-03611-3.

Cardiac PET Imaging of ATP Binding Cassette (ABC) Transporters: Opportunities and Challenges.

Liu W, Mossel P, Schwach V, Slart R, Luurtsema G Pharmaceuticals (Basel). 2023; 16(12).

PMID: 38139840 PMC: 10748140. DOI: 10.3390/ph16121715.

[C]metoclopramide is a sensitive radiotracer to measure moderate decreases in P-glycoprotein function at the blood-brain barrier.

Mairinger S, Leterrier S, Filip T, Lobsch M, Pahnke J, Hernandez-Lozano I J Cereb Blood Flow Metab. 2023; 44(1):142-152.

PMID: 37728771 PMC: 10905639. DOI: 10.1177/0271678X231202336.

Impact of Cytochrome Induction or Inhibition on the Plasma and Brain Kinetics of [C]metoclopramide, a PET Probe for P-Glycoprotein Function at the Blood-Brain Barrier.

Breuil L, Ziani N, Leterrier S, Hugon G, Caille F, Bouilleret V Pharmaceutics. 2022; 14(12).

PMID: 36559144 PMC: 9785688. DOI: 10.3390/pharmaceutics14122650.

Comparative vulnerability of PET radioligands to partial inhibition of P-glycoprotein at the blood-brain barrier: A criterion of choice?.

Breuil L, Marie S, Goutal S, Auvity S, Truillet C, Saba W J Cereb Blood Flow Metab. 2021; 42(1):175-185.

PMID: 34496661 PMC: 8721783. DOI: 10.1177/0271678X211045444.

References

Abrahim A, Luurtsema G, Bauer M, Karch R, Lubberink M, Pataraia E . Peripheral metabolism of (R)-[11C]verapamil in epilepsy patients. Eur J Nucl Med Mol Imaging. 2007; 35(1):116-23. DOI: 10.1007/s00259-007-0556-5. View

Lubberink M, Luurtsema G, van Berckel B, Boellaard R, Toornvliet R, Windhorst A . Evaluation of tracer kinetic models for quantification of P-glycoprotein function using (R)-[11C]verapamil and PET. J Cereb Blood Flow Metab. 2006; 27(2):424-33. DOI: 10.1038/sj.jcbfm.9600349. View

Syvanen S, Xie R, Sahin S, Hammarlund-Udenaes M . Pharmacokinetic consequences of active drug efflux at the blood-brain barrier. Pharm Res. 2006; 23(4):705-17. DOI: 10.1007/s11095-006-9780-0. View

Bankstahl J, Kuntner C, Abrahim A, Karch R, Stanek J, Wanek T . Tariquidar-induced P-glycoprotein inhibition at the rat blood-brain barrier studied with (R)-11C-verapamil and PET. J Nucl Med. 2008; 49(8):1328-35. PMC: 3690700. DOI: 10.2967/jnumed.108.051235. View

Eichelbaum M, Mikus G, Vogelgesang B . Pharmacokinetics of (+)-, (-)- and (+/-)-verapamil after intravenous administration. Br J Clin Pharmacol. 1984; 17(4):453-8. PMC: 1463390. DOI: 10.1111/j.1365-2125.1984.tb02371.x. View

Bartels A, Willemsen A, Kortekaas R, de Jong B, de Vries R, de Klerk O . Decreased blood-brain barrier P-glycoprotein function in the progression of Parkinson's disease, PSP and MSA. J Neural Transm (Vienna). 2008; 115(7):1001-9. PMC: 2468317. DOI: 10.1007/s00702-008-0030-y. View

Langer O, Bauer M, Hammers A, Karch R, Pataraia E, Koepp M . Pharmacoresistance in epilepsy: a pilot PET study with the P-glycoprotein substrate R-[(11)C]verapamil. Epilepsia. 2007; 48(9):1774-1784. DOI: 10.1111/j.1528-1167.2007.01116.x. View

Hurlemann R, Schlaepfer T, Matusch A, Reich H, Shah N, Zilles K . Reduced 5-HT(2A) receptor signaling following selective bilateral amygdala damage. Soc Cogn Affect Neurosci. 2008; 4(1):79-84. PMC: 2656878. DOI: 10.1093/scan/nsn039. View

Toornvliet R, van Berckel B, Luurtsema G, Lubberink M, Geldof A, Bosch T . Effect of age on functional P-glycoprotein in the blood-brain barrier measured by use of (R)-[(11)C]verapamil and positron emission tomography. Clin Pharmacol Ther. 2006; 79(6):540-8. DOI: 10.1016/j.clpt.2006.02.004. View

10.

Hammers A, Allom R, Koepp M, Free S, Myers R, Lemieux L . Three-dimensional maximum probability atlas of the human brain, with particular reference to the temporal lobe. Hum Brain Mapp. 2003; 19(4):224-47. PMC: 6871794. DOI: 10.1002/hbm.10123. View

11.

Bartels A, Kortekaas R, Bart J, Willemsen A, De Klerk O, de Vries J . Blood-brain barrier P-glycoprotein function decreases in specific brain regions with aging: a possible role in progressive neurodegeneration. Neurobiol Aging. 2008; 30(11):1818-24. DOI: 10.1016/j.neurobiolaging.2008.02.002. View

12.

Mukhin A, Kimes A, Chefer S, Matochik J, Contoreggi C, Horti A . Greater nicotinic acetylcholine receptor density in smokers than in nonsmokers: a PET study with 2-18F-FA-85380. J Nucl Med. 2008; 49(10):1628-35. PMC: 2766917. DOI: 10.2967/jnumed.108.050716. View

13.

De Klerk O, Willemsen A, Roosink M, Bartels A, Hendrikse N, Bosker F . Locally increased P-glycoprotein function in major depression: a PET study with [11C]verapamil as a probe for P-glycoprotein function in the blood-brain barrier. Int J Neuropsychopharmacol. 2009; 12(7):895-904. DOI: 10.1017/S1461145709009894. View

14.

Dagenais C, Zong J, Ducharme J, Pollack G . Effect of mdr1a P-glycoprotein gene disruption, gender, and substrate concentration on brain uptake of selected compounds. Pharm Res. 2001; 18(7):957-63. DOI: 10.1023/a:1010984110732. View

15.

Brunner M, Langer O, Sunder-Plassmann R, Dobrozemsky G, Muller U, Wadsak W . Influence of functional haplotypes in the drug transporter gene ABCB1 on central nervous system drug distribution in humans. Clin Pharmacol Ther. 2005; 78(2):182-90. DOI: 10.1016/j.clpt.2005.04.011. View

16.

Liow J, Kreisl W, Zoghbi S, Lazarova N, Seneca N, Gladding R . P-glycoprotein function at the blood-brain barrier imaged using 11C-N-desmethyl-loperamide in monkeys. J Nucl Med. 2008; 50(1):108-15. PMC: 2652692. DOI: 10.2967/jnumed.108.056226. View

17.

Loscher W, Potschka H . Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases. Prog Neurobiol. 2005; 76(1):22-76. DOI: 10.1016/j.pneurobio.2005.04.006. View